Aaron Ondrey - Rocket Pharmaceuticals Chief Officer
| RCKT Stock | USD 8.49 0.17 2.04% |
Executive
Aaron Ondrey is Chief Officer of Rocket Pharmaceuticals
| Age | 49 |
| Address | 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512 |
| Phone | 609 659 8001 |
| Web | https://www.rocketpharma.com |
Aaron Ondrey Latest Insider Activity
Tracking and analyzing the buying and selling activities of Aaron Ondrey against Rocket Pharmaceuticals stock is an integral part of due diligence when investing in Rocket Pharmaceuticals. Aaron Ondrey insider activity provides valuable insight into whether Rocket Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Rocket Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rocket Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Aaron Ondrey over six months ago Acquisition by Aaron Ondrey of 46781 shares of Rocket Pharmaceuticals subject to Rule 16b-3 |
Rocket Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3122) % which means that it has lost $0.3122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5414) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.59 in 2025. Return On Capital Employed is likely to drop to -0.59 in 2025. At this time, Rocket Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 11.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 20.6 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Olivier Danos | Regenxbio | 67 | |
| Paul Bullock | Replimune Group | N/A | |
| Colin Love | Replimune Group | 66 | |
| Eric MBA | Mirum Pharmaceuticals | 65 | |
| Gabriel MD | Solid Biosciences LLC | 47 | |
| Debra Feldman | Dyne Therapeutics | 54 | |
| Vinita Kumar | Mirum Pharmaceuticals | N/A | |
| MA JD | Sutro Biopharma | N/A | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Andrew Schwendenman | Replimune Group | 49 | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Jessie Hanrahan | Solid Biosciences LLC | 48 | |
| Joseph MD | Syndax Pharmaceuticals | N/A | |
| Audrey Bergan | Merus BV | N/A | |
| MBA MA | Replimune Group | N/A | |
| Matt Yang | Cytokinetics | N/A | |
| MBA MD | Replimune Group | 58 | |
| Erin Campany | Mirum Pharmaceuticals | 57 | |
| Steven Closter | Syndax Pharmaceuticals | N/A | |
| Eric Olson | Stoke Therapeutics | N/A | |
| Anne MD | Sutro Biopharma | 56 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.31 |
Rocket Pharmaceuticals Leadership Team
Elected by the shareholders, the Rocket Pharmaceuticals' board of directors comprises two types of representatives: Rocket Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rocket. The board's role is to monitor Rocket Pharmaceuticals' management team and ensure that shareholders' interests are well served. Rocket Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rocket Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, VP, Officer | ||
| Mayo Pujols, Chief Officer | ||
| Martin JD, Chief Counsel | ||
| Carlos Martin, Chief Officer | ||
| Jonathan Schwartz, Chief Medical Officer | ||
| Aaron Ondrey, Chief Officer | ||
| Isabel JD, Senior Officer | ||
| PharmD MBA, President COO | ||
| Raj MBA, Senior Officer | ||
| Gaurav MD, CEO Director | ||
| M MBA, Bus Lead | ||
| Jessie MBA, VP Fin | ||
| Kevin Giordano, Director Communications | ||
| MBA MBA, Pres COO | ||
| Jonathan MD, Chief Development | ||
| John CPA, Senior VP | ||
| MD JD, Senior Officer |
Rocket Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rocket Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 555.25 M | ||||
| Shares Outstanding | 106.63 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 96.99 % | ||||
| Number Of Shares Shorted | 11.24 M | ||||
| Price To Book | 1.95 X | ||||
| EBITDA | (273.2 M) | ||||
| Net Income | (258.75 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.